CataloniaBioHT participates in the Annual Advisory Committee of the Catalonia’s Cluster Programme Blog Post

Last Thursday, the president of CataloniaBio & HealthTech (CataloniaBioHT), Jaume Amat, participated in the Annual Advisory Committee of the Catalonia’s Cluster Programme, promoted by ACCIÓ, alongside the other presidents of the 30 accredited clusters. The association, founded in 2017 as a result of the merger of CataloniaBio and HeathTech Cluster and headquartered in the Barcelona Science Park, has over 160 companies and agents in the field of biomedicine and health. 

 

CataloniaBio & HealthTech and Boston MassMEDIC join forces Blog Post

CataloniaBio & HealthTech –the association of companies in the biomedicine and health arena in Catalonia, based in the Barcelona Science Park– and the Massachusetts Medical Device Industry Council (MassMEDIC), the largest association of medical technology companies in the United States, have signed an agreement to foster innovation and collaborations in business and research among their members. 

 

Europe looks to cells for a healthier future Blog Post

Researchers from the Centro Nacional de Análisis Genómico (CNAG-CRG) –based in the Barcelona Science Park and integrated into the Centre for Genomic Regulation (CRG) take part in the LifeTime consortium, which aims at understanding the constant changes within cells and their relationship to disease. The initiative will receive one million euros to devise a plan how to embed its vision into the European research and innovation landscape.

 

EIT Health Wild Card: €4 million in search of innovative health ideas Blog Post

Under the new Wild Card programme, EIT Health consortium –the largest European body for innovation in healthy living and active ageing– has announced €4 million in funding for disruptive initiatives that help transform European healthcare and mitigate the social and economic impact of the progressive ageing of the population. The Universitat de Barcelona (UB), a core partner and promoter of EIT Health Spain, is one of the 14 European institutions that will offer advisory and incubation services to the two winning teams to turn their ideas into a business plan through of the Barcelona Entrepreneurship Institute (BIE), the Bosch i Gimpera Foundation (FBG) and the Barcelona Science Park (PCB). On Monday, January 29, an informative session will take place at the PCB.

 

Embryotools successfully concludes the first trials on an innovative assisted reproduction technique Blog Post

Embryotools —headquartered at Barcelona Science Park (PCB)— has successfully concluded tests on animal models to validate an innovative assisted reproduction technique known as Maternal Spindle Transfer (MST).  This new technique is a mitochondrial replacement therapy which groups of leading scientists from around the world are studying for the prevention of mitochondrial diseases, which are transmitted maternally and currently have no treatment. Embryotools has been working on this project for over three years in partnership with the PCB-PRBB Animal Facility Alliance and the company Reprogenetics UK, located at Oxford University.

 

A pioneer project to promote organ donation in the European Union and neighbouring countries Blog Post

Raising awareness among society and promoting the training around highly specialized experts in the 28 member countries of the European Union and its neighbouring countries in the community area, aiming to improve the rate of organ donations are the main reference points for EUDONORGAN. This European project is led by the University of Barcelona (UB), together with Bosch i Gimpera Foundation (FBG) and the DTI Donation & Transplantation Institute, located at the Barcelona Science Park.

 

Iproteos closes a round of funding valued at 1.5 millon Euros Blog Post

Iproteos – based at the Barcelona Science Park– has closed a round of funding valued at 1.5 millon Euros, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech ASCIL Biopharm. The company will set aside this injection of capital to the completion of the regulatory preclinical phase of his compound, a first-in-class drug for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound is one of the few that are being developed around the world to halt and reverse the cognitive impairment caused by this disease.

 

The Biotechnology Business Institute expands its masters programs Blog Post

Following the success of the Master in Project Management applied to biotechnology and pharmaceutical industry –which is now in the third edition–and the growing professional demand for health science profiles with knowledge in applied management, the Biotechnology Business Institute -based at the Barcelona Science Park (PCB)- is expanding its continuing education offer with two new programs: the Master in Marketing Management and the Master in Business Management.